There are 744 papers on lipoprotein in aging research: 98 trials and 354 observational studies in people, 3 in animals, 3 in cells, 267 reviews.
691 new papers in 30 daysSee all 6,010 papers on lipoprotein
“Percent change in OxPL-apo(a) correlated more closely than OxPL-apoB with percent change in Lp(a) than did OxPL-apoB.”
- Human trial98
- Humans354
- Animals3
- Cells3
- In silico4
Interventions
70Pelacarsen
downin humans12downin reviews1−99% to −80%
13 studies
Pelacarsen
downin humans12downin reviews1−99% to −80%
Pelacarsen decreases lipoprotein in humans (86% placebo-adjusted reduction; between-group GMR 0.14 (95% CI 0.11–0.18)).
“GMR between groups (pelacarsen/placebo) was 0.14 (95% CI: 0.11, 0.18; P<0.0001), equivalent to an 86% placebo-adjusted reduction.”
Human trialUS Black/African American and Hispanic participants with elevated lipoprotein(a) and established atherosclerotic cardiovascular disease80 mg monthly52 weeksn = 422
Circulation. Population health and outcomes
Pelacarsen decreases lipoprotein in humans (Preexisting cardiovascular disease and lipoprotein(a) of at least 70 mg per deciliter) (64.4 versus 233.4 nmol per liter with placebo at 12 months).
“At 12 months, the lipoprotein(a) level was 64.4 nmol per liter in the pelacarsen group and 233.4 nmol per liter in the placebo group.”
Human trialPreexisting cardiovascular disease and lipoprotein(a) of at least 70 mg per deciliterantisense oligonucleotideserum80 mg monthly12 months27.0% womensn = 8,322
Pelacarsen did not lower major cardiovascular event risk
The New England journal of medicine
Pelacarsen decreases lipoprotein in humans (-72% (95% CI: -79%, -61%; P < .0001)).
“The placebo-adjusted Lp(a) change from baseline at week 52 was -72% (95% CI: -79%, -61%; P < .0001).”
Human trialinjection80 mg52 weeks
Pelacarsen and lipoprotein(a) apheresis in secondary prevention: the Lp(a)FRONTIERS APHERESIS trial
European heart journal
Pelacarsen decreases lipoprotein in humans (MD -54.15 percentage points, 95% CI -76.75 to -31.55).
“pelacarsen (MD - 54.15, 95% CI -76.75 to -31.55)”
Review
Frontiers in endocrinology
Pelacarsen decreases lipoprotein in humans (compared with placebo) (−29.0 mg/dL at 20 mg Q4W to −66.0 mg/dL at 60 mg Q4W).
“Pelacarsen reductions ranged from –29.0 mg/dL (20 mg Q4W) to –66.0 mg/dL (60 mg Q4W).”
Reviewcompared with placeboantisense oligonucleotide20–60 mg Q4W
AHA Scientific Sessions 2026 abstract
Pelacarsen decreases lipoprotein in humans (patients with established cardiovascular disease in Lp(a)HORIZON; topline results only).
“Topline results announced in September 2026 indicated that pelacarsen lowered Lp(a) but did not reduce the primary composite cardiovascular endpoint in patients with established cardiovascular disease.”
Reviewpatients with established cardiovascular disease in Lp(a)HORIZON; topline results onlyhepatocyte-directed antisense oligonucleotide
The American journal of medicine
Pelacarsen decreases lipoprotein in humans (sponsor-reported Lp(a)HORIZON topline data; complete peer-reviewed results unavailable).
“pelacarsen lowered Lp(a) but did not significantly reduce the prespecified primary cardiovascular endpoint in the overall Lp(a)HORIZON population”
Reviewsponsor-reported Lp(a)HORIZON topline data; complete peer-reviewed results unavailable
Biomedicines
Pelacarsen decreases lipoprotein in humans (up to 99%).
“demonstrated Lp(a) reductions of up to 99%”
Review
Targeting Lipoprotein(a): A New Era in Cardiovascular Disease Prevention
Methodist DeBakey cardiovascular journal
Pelacarsen decreases lipoprotein in humans (up to 80-95% reductions).
“Emerging Lp(a)-specific therapies, including pelacarsen, olpasiran, muvalaplin, and SLN360, demonstrate up to 80-95% reductions in Lp(a)”
Review
Lipoprotein(a) in Japan: An Expert Consensus Statement
Journal of atherosclerosis and thrombosis
Pelacarsen decreases lipoprotein in humans (Up to 80% reduction).
“Antisense oligonucleotide therapy with pelacarsen reduced Lp(a) levels by up to 80%”
Reviewplasma
Efficacy and tolerability of targeted lipoprotein(a)-lowering therapies: A systematic review
Journal of clinical lipidology
All 13Fewer
Olpasiran
downin humans9
9 studies
Olpasiran
downin humans9
Olpasiran decreases lipoprotein in humans (network meta-analysis versus placebo) (MD −87.72%; 95% CI −113.78 to −61.66).
“Compared to placebo, olpasiran showed the largest reduction in Lp(a) (MD: –87.72%; 95% CI: –113.78 to –61.66)”
Human trialnetwork meta-analysis versus placebosmall interfering RNAn = 1,185
AHA Scientific Sessions 2025 abstract
Olpasiran decreases lipoprotein in patients with ASCVD and elevated Lp(a).
“In patients with ASCVD and elevated Lp(a), olpasiran reduces Lp(a) irrespective of apo(a) isoform size”
Human trialin patients with ASCVD and elevated Lp(a)36 weeks
Efficacy of Olpasiran by Apolipoprotein(a) Isoform Size: Insights from the OCEAN(a)-DOSE Trial
AHA Scientific Sessions 2025 abstract
Olpasiran decreases lipoprotein in humans (versus placebo) (MD -98.34 nmol/L (95% CI -102.75 to -93.92)).
“Olpasiran demonstrated a significant reduction in Lp(a) levels compared to placebo (MD: -98.34 nmol/L, 95% CI: [-102.75; -93.92], p < 0.0001)”
Human trialversus placebo
ENDO 2025 abstract
Olpasiran decreases lipoprotein in humans (MD -92.06 percentage points, 95% CI -107.91 to -76.21).
“Among Lp(a)-targeted therapies, substantial percentage-point differences were observed with olpasiran (MD -92.06, 95% CI -107.91 to -76.21)”
Review
Frontiers in endocrinology
Olpasiran decreases lipoprotein in humans (Compared with control in pooled randomized controlled trials) (MD −93.48%; 95% CI −110.55 to −76.42).
“The greatest reductions were observed with olpasiran (MD, –93.48%; 95% CI, –110.55 to –76.42)”
ReviewCompared with control in pooled randomized controlled trials
AHA Scientific Sessions 2026 abstract
Olpasiran decreases lipoprotein in humans (compared with placebo) (MD −100.5 mg/dL, 95% CI −105.5 to −95.5).
“The largest reductions were observed with olpasiran 225 mg (MD –100.5 mg/dL, 95% CI –105.5 to –95.5)”
Reviewcompared with placebosiRNA225 mg
AHA Scientific Sessions 2026 abstract
Olpasiran decreases lipoprotein in humans (> 95% reduction).
“olpasiran (> 95% reduction, OCEAN(a)-Outcomes)”
Reviewsmall interfering RNA
Novel Lipoprotein (a) Therapies: A Comprehensive Review
Current atherosclerosis reports
Olpasiran decreases lipoprotein in humans (percentage Lp(a) change versus placebo) (mean difference -92.06% (95% CI -109.80 to -74.32) versus placebo).
“Compared with placebo, Olpasiran was the most effective therapy for both percentage [mean difference: -92.06, 95% (-109.80; -74.32), P-score: 0.94] and absolute reductions”
Reviewpercentage Lp(a) change versus placebo
Frontiers in cardiovascular medicine
Olpasiran decreases lipoprotein in the OCEAN(a)-DOSE trial, in patients with established ASCVD and Lp(a) > 150 nmol/L (greater than 95% reduction).
“demonstrated greater than 95% reduction in Lp(a)”
Reviewin the OCEAN(a)-DOSE trial, in patients with established ASCVD and Lp(a) > 150 nmol/Lsmall interfering RNA (siRNA)
Lowering of Lipoprotein(a) with Olpasiran
Cardiovascular & hematological disorders drug targets
Levocarnitine
downin humans5no changein humans2
6 studies
Levocarnitine
downin humans5no changein humans2
Levocarnitine decreases lipoprotein in humans (mixed hyperlipidemia and elevated Lp(a) concentration) (-19.4% (p = 0.01; p = 0.016 vs placebo/simvastatin)).
“Lp(a) was significantly reduced in the L-carnitine/simvastatin group [-19.4%, from 52 (20-171) to 42 (15-102) mg/dL; p = 0.01]”
Human trialmixed hyperlipidemia and elevated Lp(a) concentration2 g/day L-carnitine plus 20 mg/day simvastatin12 weeksn = 29
Lipids
Levocarnitine showed no clear effect on lipoprotein in humans (hemodialysis patients with Lp (a) hyperlipoproteinemia).
“There were no significant differences between the two groups in mean changes of serum interleukin-1β, tumor necrosis factor-α, Lp (a), and oxidized low-density lipoprotein concentrations.”
Human trialhemodialysis patients with Lp (a) hyperlipoproteinemiaoralserum1000 mg/d12 weeksn = 36
Hemodialysis international. International Symposium on Home Hemodialysis
Levocarnitine decreases lipoprotein in humans (co-administered with simvastatin, compared with simvastatin alone).
“Lp(a) serum levels increase from baseline to 60 days in the simvastatin group alone versus a significant decrease in the combination group.”
Human trialco-administered with simvastatin, compared with simvastatin alone2 g/day60 days
Atherosclerosis
Levocarnitine decreases lipoprotein in humans (versus placebo at 6 months) (P < 0.05 vs placebo).
“We observed a significant improvement after 6 months (P < 0.05) in the Lp(a) value in patients taking L-carnitine compared with those taking placebo.”
Human trialversus placebo at 6 months1-g oral tablet1 g twice daily6 monthsn = 94
Clinical therapeutics
Levocarnitine decreases lipoprotein in humans (hyper Lp(a)) (-11.7% vs placebo treatment).
“L-carnitine (2 g/day) significantly reduced Lp(a) levels (-7.7% vs baseline and -11.7% vs placebo treatment)”
Human trialhyper Lp(a)2 g/day
L-carnitine reduces plasma lipoprotein(a) levels in patients with hyper Lp(a)
Nutrition, metabolism, and cardiovascular diseases : NMCD
Levocarnitine showed no clear effect on lipoprotein in humans (intravenous administration) (WMD: -2.91 mg/dL, 95% CI: -10.22, 4.41, p = 0.436).
“but not intravenous L-carnitine (WMD: -2.91 mg/dL, 95% CI: -10.22, 4.41, p = 0.436).”
Reviewintravenous administration
Scientific reports
Levocarnitine decreases lipoprotein in humans (all RCTs) (WMD: -8.82 mg/dL, 95% CI: -10.09, -7.55, p < 0.001).
“The meta-analysis showed a significant reduction of Lp(a) levels following L-carnitine supplementation (WMD: -8.82 mg/dL, 95% CI: -10.09, -7.55, p < 0.001).”
Reviewall RCTs
Scientific reports
Muvalaplin
downin humans5downin silico1−86% to −65%
6 studies
Muvalaplin
downin humans5downin silico1−86% to −65%
Muvalaplin decreases lipoprotein in humans (MD -61.49 percentage points, 95% CI -80.26 to -42.72).
“muvalaplin (MD -61.49, 95% CI -80.26 to -42.72)”
Review
Frontiers in endocrinology
Muvalaplin decreases lipoprotein in silico (Population PK/PD simulations using Phase 1 and Phase 2 data) (Model-predicted reduction of up to 86%).
“Simulations of percent change from baseline for Lp(a) suggested a model predicted reduction of up to 86% with increasing dose levels”
In silicoPopulation PK/PD simulations using Phase 1 and Phase 2 data10 mg to 240 mg
AHA Scientific Sessions 2026 abstract
Muvalaplin decreases lipoprotein in humans (Phase 2 testing).
“An oral small molecule, muvalaplin, achieved comparable reductions in phase 2 testing.”
ReviewPhase 2 testing
Current atherosclerosis reports
Muvalaplin decreases lipoprotein in humans (early-phase studies).
“muvalaplin, an oral small-molecule inhibitor targeting Lp(a) assembly, has shown promising reductions in Lp(a) levels in early-phase studies.”
Reviewearly-phase studiesplasma
Efficacy and tolerability of targeted lipoprotein(a)-lowering therapies: A systematic review
Journal of clinical lipidology
Muvalaplin decreases lipoprotein in humans (up to 85.8%).
“reduces intact Lp(a) by up to 85.8% in phase 2 KRAKEN trials”
Revieworal small-molecule
Novel Lipoprotein (a) Therapies: A Comprehensive Review
Current atherosclerosis reports
Muvalaplin decreases lipoprotein in humans (up to 65%).
“In Phase I trials, daily administration of muvalaplin for 14 days reduced Lp(a) levels by up to 65%.”
Review14 days
Muvalaplin: A Novel Oral Therapy for Targeted Reduction of Plasma Lipoprotein(a)
Cardiovascular & hematological disorders drug targets
Inclisiran
downin humans5−33% to −18%
5 studies
Inclisiran
downin humans5−33% to −18%
Inclisiran decreases lipoprotein in humans (added to statin therapy) (27% reduction (70 to 51 mg/dL)).
“and Lp(a) reduction of 27% (baseline 70 ± 15 → 51 ± 12 mg/dL, p<0.001)”
Human trialadded to statin therapy300 mg subcutaneously at baseline, 3 months, then every 6 months24 monthsn = 172
ESC Congress 2026 abstract
Inclisiran decreases lipoprotein in humans (elevated LDL-C, low/moderate ASCVD risk, monotherapy) (-30.27%).
“inclisiran induced a significant (P < 0.0001) reduction in other atherogenic lipoproteins and lipid biomarkers (placebo-adjusted LSM difference: lipoprotein(a), -30.27%”
Human trialelevated LDL-C, low/moderate ASCVD risk, monotherapy150 daysn = 207
Journal of clinical lipidology
Inclisiran decreases lipoprotein in humans (dyslipidemia and atherosclerotic plaques in peripheral arteries) (-33%).
“and Lp(a) by 33%”
Human trialdyslipidemia and atherosclerotic plaques in peripheral arteries90 daysn = 22
Kardiologiia
Inclisiran is linked with lower lipoprotein in humans (unadjusted analyses) (-8% to -17%).
“and from -8% to -17% with inclisiran”
Humansunadjusted analyses
Atherosclerosis
Inclisiran decreases lipoprotein in humans (meta-analyses of RCTs) (18.00%).
“and inclisiran (18.00%; high certainty).”
Reviewmeta-analyses of RCTs
Drugs
Antisense oligonucleotides
downin humans5−90%
5 studies
Antisense oligonucleotides
downin humans5−90%
Antisense oligonucleotides decrease lipoprotein in humans (Elevated Lp(a); ASO trials versus placebo) (−74 to −80 nmol/L).
“ASO trials demonstrated more modest reductions (−74 to −80 nmol/L) with greater variability.”
ReviewElevated Lp(a); ASO trials versus placebo
ESC Congress 2026 abstract
Antisense oligonucleotides decrease lipoprotein in humans (65% to >95%).
“RNA-targeted agents, comprising antisense oligonucleotides and small interfering RNAs, together with a first oral small-molecule inhibitor, lower Lp(a) by about 65% to more than 95%”
Review
Lipoprotein(a) in the statin era: from risk marker to therapeutic target
Frontiers in pharmacology
Antisense oligonucleotides decrease lipoprotein in humans (up to 90%).
“Novel therapies-including antisense oligonucleotides, siRNA therapeutics, CETP inhibitors, and experimental gene-editing approaches-show promising potential, reducing Lp(a) levels by up to 90%.”
Review
Lipoprotein(a) as a Cardiovascular Risk Factor: Clinical Significance and Therapeutic Perspectives
Biomedicines
Antisense oligonucleotides decrease lipoprotein in humans (Phase II trials).
“antisense oligonucleotides and small interfering RNAs) and a small molecule inhibitor of Lp(a) synthesis, demonstrated substantial and often durable Lp(a)-lowering effects in Phase II trials.”
ReviewPhase II trials
Lipoprotein(a)-lowering therapies: a promising future
European heart journal
Antisense oligonucleotides decrease lipoprotein in humans.
“Novel therapeutics, including antisense oligonucleotides, small interfering RNAs, and small molecular inhibitors, have shown promising Lp(a)-lowering effects”
Review
Journal of lipid and atherosclerosis
PCSK9 inhibitors
downin humans2downin reviews2
4 studies
PCSK9 inhibitors
downin humans2downin reviews2
PCSK9 inhibitors are linked with lower lipoprotein in humans (-15.3%, -16.7%, -19.0% at 3, 9 and 21 months).
“PCSK9i therapy resulted in a significant and sustained reduction in lipoprotein(a), with mean changes of -15.3%, -16.7%, and -19.0% at 3, 9, and 21 months, respectively (all p < 0.001).”
Humans21 monthsn = 1,112
Atherosclerosis
PCSK9 inhibitors decrease lipoprotein (20%-30% reduction).
“PCSK9 inhibitors (eg, alirocumab, evolocumab, and tafolecimab) not only reduced low-density lipoprotein (LDL-C) by 55%-60% but also lowered Lp(a) by 20%-30%.”
Review
Journal of cardiovascular pharmacology
PCSK9 inhibitors decrease lipoprotein in humans (15-20% reduction, smaller than effect on LDL-C).
“PCSK9 inhibitors have been found to reduce Lp(a) levels but to a lesser extent than their effect on LDL-C”
Review
Lowering of Lipoprotein(a) with Olpasiran
Cardiovascular & hematological disorders drug targets
PCSK9 inhibitors decrease lipoprotein.
“reducing the lipoprotein concentration and slowing thrombosis”
Review
PCSK9 Inhibition: From Current Advances to Evolving Future
Cells
RNA-targeted therapies
downin humans3
3 studies
RNA-targeted therapies
downin humans3
RNA-targeted therapies decrease lipoprotein in humans (Elevated Lp(a) (≥125 nmol/L or ≥50 mg/dL); compared with placebo) (−86.6 nmol/L (95% CI −98.5 to −74.7); 82–95% relative suppression).
“Across all RNA-targeted therapies, pooled analysis demonstrated a mean absolute Lp(a) reduction of −86.6 nmol/L (95% CI −98.5 to −74.7; I2=99%)”
ReviewElevated Lp(a) (≥125 nmol/L or ≥50 mg/dL); compared with placebon = 8,799
ESC Congress 2026 abstract
RNA-targeted therapies decrease lipoprotein in humans (phase 2 randomized trials) (80-95% or more).
“RNA-targeted therapies - antisense oligonucleotides and small interfering RNA agents - and an oral inhibitor of Lp(a) particle assembly have produced pharmacodynamic Lp(a) reductions of 80-95% or more in phase 2 randomized trials.”
Reviewphase 2 randomized trials
Targeting Lipoprotein(a) in Cardiovascular Disease: Emerging Therapies and Clinical Implications
Journal of cardiovascular pharmacology
RNA-targeted therapies decrease lipoprotein in humans (80-95% reductions).
“novel RNA-targeted therapies achieve unprecedented 80-95% reductions”
Review
The Lipoprotein(a) Implementation Gap: Bridging Evidence and Clinical Practice
Reviews in cardiovascular medicine
Coenzyme Q10
downin humans3
3 studies
Coenzyme Q10
downin humans3
Coenzyme Q10 decreases lipoprotein in humans.
“serum levels of lipoprotein(a) reduced significantly in the carnitine, coenzyme Q10, and combination groups”
Human trialcompared with baseline and with placebo at 3 months in statin-treated hemodialysis patients3 months
Iranian journal of kidney diseases
Coenzyme Q10 decreases lipoprotein in humans (acute coronary disease with moderately raised lipoprotein(a)) (31.0% reduction versus 8.2% with placebo; net reduction 22.6%).
“Serum lipoprotein(a) showed significant reduction in the coenzyme Q10 group compared with the placebo group”
Human trialacute coronary disease with moderately raised lipoprotein(a)hydrosoluble Q-Gel60 mg twice daily28 days
International journal of cardiology
Coenzyme Q10 decreases lipoprotein in humans (WMD: -3.54 mg/dL, 95% CI: -5.50, -1.58).
“Overall, CoQ10 supplementation was paralleled by a slight but significant reduction of plasma Lp(a) levels (WMD: -3.54 mg/dL, 95% CI: -5.50, -1.58; p<0.001)”
Reviewn = 409
Pharmacological research
Growth hormone
upin humans3
3 studies
Growth hormone
upin humans3
Growth hormone increases lipoprotein in humans (abdominal obesity; compared with placebo).
“Serum lipoprotein(a) [Lp(a)] concentration increased (P<0.05 vs. placebo).”
Human trialabdominal obesity; compared with placebo9 monthsmalesn = 30
Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society
Growth hormone increases lipoprotein in humans (treatment of GH-deficient adults and girls with Turner syndrome) (119 +/- 35% in GH-deficient adults; 126 +/- 44% in girls with Turner syndrome).
“We conclude that long-term GH treatment increases and IGF-I decreases circulating levels of Lp(a).”
Human trialtreatment of GH-deficient adults and girls with Turner syndrome6-9 months
Growth hormone increases and insulin-like growth factor-I decreases circulating lipoprotein(a)
European journal of endocrinology
Growth hormone increases lipoprotein in hypopituitary adults (P < 0.05).
“During 12 months of GH therapy, a significant increase in serum lipoprotein-(a) was observed (P < 0.05).”
Human trialin hypopituitary adultsrecombinant humanmean 0.2 IU/kg.week12 monthsn = 22
The Journal of clinical endocrinology and metabolism
Acetylcysteine
no changein humans2downin humans1
2 studies
Acetylcysteine
no changein humans2downin humans1
Acetylcysteine showed no clear effect on lipoprotein in humans.
“There was no significant effect on plasma Lp(a) levels.”
Human trialn = 11
N-acetylcysteine treatment lowers plasma homocysteine but not serum lipoprotein(a) levels
Atherosclerosis
Acetylcysteine decreases lipoprotein in subjects with high plasma level of Lp(a) (-7% (P = 0.02)).
“a small but significant decrease in Lp(a) concentration of 7% (P = 0.02) was observed after administration of NAC in a dose of 1.2 g d-1 for 6 weeks”
Human trialin subjects with high plasma level of Lp(a)1.2 g d-16 weeksn = 12
N-acetylcysteine and serum concentrations of lipoprotein(a)
Journal of internal medicine
Acetylcysteine showed no clear effect on lipoprotein in subjects with median Lp(a) 14.3 mg dl-1.
“plasma level of Lp(a) was not changed by administration of NAC 1.2 g d-1 for 4 weeks in 7 subjects”
Human trialin subjects with median Lp(a) 14.3 mg dl-11.2 g d-14 weeksn = 7
N-acetylcysteine and serum concentrations of lipoprotein(a)
Journal of internal medicine
Enlicitide
downin humans2
2 studies
Enlicitide
downin humans2
Enlicitide decreases lipoprotein in humans (placebo-corrected; effect shown for baseline Lp(a) ≥125 nmol/L) (absolute -45.8 nmol/L (95% CI -52.6, -39.2) at baseline ≥125 nmol/L; -8.4 nmol/L below 125 nmol/L).
“Placebo-corrected %Lp(a) reduction with enlicitide was significant across all baseline Lp(a) levels (p<0.001 for all)”
Human trialplacebo-corrected; effect shown for baseline Lp(a) ≥125 nmol/L20 mg24 weeksn = 3,187
An oral drug lowers lipoprotein(a) across patient groups
ESC Congress 2026 abstract
Enlicitide decreases lipoprotein in humans (placebo-controlled, week 24).
“the percent change in lipoprotein(a) levels at week 24 were significantly greater with enlicitide than with placebo”
Reviewplacebo-controlled, week 2420 mg daily24 weeks
A Placebo-Controlled Trial of the Oral PCSK9 Inhibitor Enlicitide
The New England journal of medicine
Alirocumab
downin humans2
2 studies
Alirocumab
downin humans2
Alirocumab decreases lipoprotein in humans (recent acute coronary syndromes) (mean 25% reduction in time-weighted Lp(a)).
“Alirocumab reduced time-weighted Lp(a) by a mean 25%.”
Human trialrecent acute coronary syndromes
ESC Congress 2026 abstract
Alirocumab decreases lipoprotein in humans (meta-analyses of RCTs) (18.55-26.46%).
“alirocumab (18.55-26.46%; high certainty), and inclisiran (18.00%; high certainty).”
Reviewmeta-analyses of RCTs150 mg biweekly
Drugs
Curcumin
downin humans2
2 studies
Curcumin
downin humans2
Curcumin decreases lipoprotein in type 2 diabetic patients with mild to moderate CAD (P = 0.043).
“Nano-curcumin significantly mitigated the hs-CRP and LipoPr (a) levels following 90 days of treatment”
Human trialin type 2 diabetic patients with mild to moderate CAD80 mg/day90 daysn = 64
BioFactors (Oxford, England)
Curcumin decreases lipoprotein in humans (dietary supplementation with highly bioavailable forms) (SMD -0.96, 95% CI -1.82 to -0.11).
“dietary supplementation with highly bioavailable forms of curcumin significantly reduces Lp(a) levels [Standardized Mean Difference (SMD)= -0.96 (95 % Confidence Interval (CI): -1.82, -0.11)].”
Reviewdietary supplementation with highly bioavailable forms
Prostaglandins & other lipid mediators
HRS-5632
downin humans1
1 study
HRS-5632
downin humans1
HRS-5632 decreases lipoprotein in humans (Healthy participants with lipoprotein(a) ≥75 nmol/L) (≥90% reduction at ≥10 mg; at week 48, ≥90% reduction in 87.5% and 100.0% of the 200 mg and 400 mg cohorts, respectively).
“HRS-5632 at 10 mg or higher could reduce lipoprotein(a) by ≥90%.”
Human trialHealthy participants with lipoprotein(a) ≥75 nmol/L10 mg or higherapproximately one year at 200 mg or 400 mgn = 40
AHA Scientific Sessions 2026 abstract
All 70Fewer
Effects
55Mortality
no changein humans5HR 0.63–1.04
5 studies
Mortality
no changein humans5HR 0.63–1.04
Lipoprotein was not clearly linked with mortality in humans (HR 1.04, 95% CI 0.84–1.28; p = 0.734).
“The multivariable adjusted Cox regression confirmed the absence of a significant association between Lp(a) concentrations and total mortality”
HumansHistory of hospitalized acute myocardial infarction; high lipoprotein(a) (≥ 50 mg/dL) versus low (< 50 mg/dL)Median follow-up: 18.2 yearsn = 617
Lipids in health and disease
Lipoprotein was not clearly linked with mortality in humans (Elevated versus nonelevated Lp(a), with LDL-C <70 mg/dL on statin and/or ezetimibe therapy).
“Stroke/TIA and all-cause mortality did not differ between groups.”
HumansElevated versus nonelevated Lp(a), with LDL-C <70 mg/dL on statin and/or ezetimibe therapyLp(a) ≥50 mg/dL or ≥125 nmol/LMedian follow-up of 2.6 to 3.1 years42.3% femalesn = 41,750
AHA Scientific Sessions 2026 abstract
Lipoprotein was not clearly linked with mortality in humans (Black adults; elevated versus normal lipoprotein(a)) (RR 0.835; p=0.213).
“not associated with 3-point major adverse cardiovascular events (RR 0.978, p=0.856), myocardial infarction (RR 1.250, p=0.202), all-cause mortality (RR 0.835, p=0.213)”
HumansBlack adults; elevated versus normal lipoprotein(a)1 year
AHA Scientific Sessions 2026 abstract
Lipoprotein was not clearly linked with mortality in patients with established ASCVD (HR 0.63, 95% CI: 0.38-1.06, p = 0.78).
“10-year all-cause mortality (HR 0.63, 95% CI: 0.38-1.06, p = 0.78).”
Humansin patients with established ASCVD10-yearn = 798
European journal of preventive cardiology
Lipoprotein was not clearly linked with mortality in humans (acute decompensated heart failure without hypertension) (P ≥ 0.41).
“However, there were no associations between mortality and Lp(a) in those without hypertension (P ≥ 0.41).”
Humansacute decompensated heart failure without hypertension4.1 years (median)
International journal of cardiology. Cardiovascular risk and prevention
Venous thromboembolism
no changein humans2no changein reviews1HR 0.99
3 studies
Venous thromboembolism
no changein humans2no changein reviews1HR 0.99
Lipoprotein was not clearly linked with venous thromboembolism in humans (High versus low lipoprotein(a) concentrations in Black and White individuals).
“Elevated Lp(a) was not associated with venous thromboembolism in either group”
HumansHigh versus low lipoprotein(a) concentrations in Black and White individuals
Cardiovascular Risk Associated with High vs Low Lipoprotein(a) Across Black and White Individuals
AHA Scientific Sessions 2026 abstract
Lipoprotein showed no clear effect on venous thromboembolism in humans (Cohort studies) (HR 0.99, 95% CI 0.85–1.15).
“cohort studies showed no association (HR 0.99 [0.85-1.15]; I2 = 0%)”
ReviewCohort studies
Atherosclerosis
Lipoprotein showed no clear effect on venous thromboembolism (genetic association studies).
“genetic association studies have not demonstrated an association between high plasma levels of Lp(a) and the risk of venous thromboembolism”
Reviewgenetic association studies
Lipoprotein(a), platelet function and cardiovascular disease
Nature reviews. Cardiology
Stroke
no changein humans3OR 0.97
3 studies
Stroke
no changein humans3OR 0.97
Lipoprotein was not clearly linked with stroke in humans (OR 0.97, 95% CI 0.86-1.09).
“not with stroke/TIA (OR 0.97, 95% CI 0.86-1.09)”
Humansn = 23,654
Journal of clinical lipidology
Lipoprotein was not clearly linked with stroke in humans (elevated Lp(a) >= 125 nmol/L) (HR 0.95, 95% CI 0.75-1.20).
“but not stroke (HR 0.95, 95% CI 0.75-1.20; P = 0.649).”
Humanselevated Lp(a) >= 125 nmol/L
ADA Scientific Sessions 2026 abstract
Lipoprotein was not clearly linked with stroke in humans.
“but not with stroke”
Humans
Journal of atherosclerosis and thrombosis
Major adverse cardiovascular events
no changein humans2
2 studies
Major adverse cardiovascular events
no changein humans2
Lipoprotein was not clearly linked with major adverse cardiovascular events in humans following the commencement of a statin in CAD patients (adjusted hazard ratio = 1.29, 95% CI = 0.52-3.18, P = .586).
“a percent change in Lp(a) levels of ≥20% following the commencement of a statin was not associated with a greater risk of subsequent MACE”
Humansfollowing the commencement of a statin in CAD patients65.1 monthsn = 100
Journal of clinical lipidology
Lipoprotein was not clearly linked with major adverse cardiovascular events in humans (established ASCVD) (aHR 1.02 (95% CI 0.98-1.06) per 10 mg/dl increment).
“there was no significant association between Lp(a) and MACE risk (aHR: 1.02 [0.98-1.06] per 10 mg/dl increment, P = 0.341”
Humansestablished ASCVDn = 2,333
Age and ageing
Inflammation
upin humans1upin reviews1
2 studies
Inflammation
upin humans1upin reviews1
Lipoprotein increases inflammation.
“Lp(a) contributes to endothelial dysfunction, promotes vascular inflammation and enhances lipid retention and oxidation within the arterial wall.”
Reviewarterial wall
Presumed Mechanisms Underlying Lipoprotein(a)-caused Atherosclerosis
European cardiology
Lipoprotein induces inflammation in humans.
“Evidence is accumulating that Lp(a) can exacerbate pathophysiological processes in CAVD, specifically, endothelial dysfunction, formation of foam cells, and promotion of a pro-inflammatory state.”
Review
Lipoprotein(a): Expanding our knowledge of aortic valve narrowing
Trends in cardiovascular medicine
Coronary artery disease
no changein humans2HR 1.3
2 studies
Coronary artery disease
no changein humans2HR 1.3
Lipoprotein was not clearly linked with coronary artery disease in humans (Lebanese adult tertiary-care cohort).
“Logistic regression analysis showed no significant association between Lp(a) levels and cardiovascular factors including dyslipidemia, hypertension, coronary artery disease, previous coronary artery bypass graft, and previous myocardial infarction.”
HumansLebanese adult tertiary-care cohortn = 456
Journal of clinical medicine
Lipoprotein was not clearly linked with coronary artery disease in humans (elevated Lp(a) without MetS compared to normal Lp(a) without MetS) (HR: 1.30; 95% CI: 0.94, 1.80).
“those with elevated Lp(a) without MetS (group 2) did not have increased risk of CHD (HR: 1.30; 95% CI: 0.94, 1.80).”
Humanselevated Lp(a) without MetS compared to normal Lp(a) without MetS
Lipoprotein(a) and Metabolic Syndrome are Associated with Increased Risk of Coronary Heart Disease
AHA Scientific Sessions 2025 abstract
Circulating coagulation proteins
no changein humans1
1 study
Circulating coagulation proteins
no changein humans1
Lipoprotein was not clearly linked with circulating coagulation proteins in humans After multiple testing correction.
“After multiple testing correction, genetically predicted lipoprotein(a) had no significant association with any coagulation proteins.”
HumansAfter multiple testing correction
Journal of thrombosis and thrombolysis
Recurrent venous thromboembolism
no changein humans1HR 1.03
1 study
Recurrent venous thromboembolism
no changein humans1HR 1.03
Lipoprotein was not clearly linked with recurrent venous thromboembolism in humans (Per genetically predicted 100 nmol/L increase) (HR 1.03, 95% CI 0.91–1.16).
“There was no association with recurrent VTE (hazard ratio 1.03, 95% CI 0.91–1.16, P = 0.68).”
HumansPer genetically predicted 100 nmol/L increasen = 1,775
Journal of thrombosis and thrombolysis
Adverse offspring health outcomes
no changein humans1
1 study
Adverse offspring health outcomes
no changein humans1
Lipoprotein was not clearly linked with adverse offspring health outcomes in humans (genetically predicted low lipoprotein(a); summary-level analyses).
“In summary-level analyses, no significant adverse associations of genetically predicted low lipoprotein(a) with reproductive and offspring health outcomes were detected.”
Humansgenetically predicted low lipoprotein(a); summary-level analyses
Genetic insights into lipoprotein(a) lowering and reproductive and offspring health outcomes
European heart journal open
Adverse reproductive health outcomes
no changein humans1
1 study
Adverse reproductive health outcomes
no changein humans1
Lipoprotein was not clearly linked with adverse reproductive health outcomes in humans (genetically predicted low lipoprotein(a); summary-level analyses).
“In summary-level analyses, no significant adverse associations of genetically predicted low lipoprotein(a) with reproductive and offspring health outcomes were detected.”
Humansgenetically predicted low lipoprotein(a); summary-level analysesfemales
Genetic insights into lipoprotein(a) lowering and reproductive and offspring health outcomes
European heart journal open
Urine albumin
downin humans1
1 study
Urine albumin
downin humans1
Lipoprotein decreases urine albumin in humans (predominantly African American elderly cohort with CKD and high Lp(a)) (y = -0.028x).
“UA however had a clear negative correlation with Lp(a), y = -0.028x.”
Human trialpredominantly African American elderly cohort with CKD and high Lp(a)n = 44
Diabetes
Estimated glomerular filtration rate
downin humans1
1 study
Estimated glomerular filtration rate
downin humans1
Lipoprotein decreases estimated glomerular filtration rate in humans (predominantly African American elderly cohort with CKD and high Lp(a)) (y = -0.029x).
“Lp(a) had a negative correlation with eGFR, y = -0.029x.”
Human trialpredominantly African American elderly cohort with CKD and high Lp(a)n = 44
Diabetes
All 55Fewer
Upstream
8Menopause
upin humans1
1 study
Menopause
upin humans1
Menopause is linked with higher lipoprotein in women with intermediate baseline Lp(a) (75-125 nmol/L) (median increase of 34.9 nmol/L).
“those who transitioned through menopause experienced a median increase of 34.9 nmol/L, approximately fourfold greater than women who remained pre- or postmenopausal”
Humansin women with intermediate baseline Lp(a) (75-125 nmol/L)median 4 yearsfemales
Menopause linked to crossing a heart disease risk threshold
European journal of preventive cardiology
Pregnancy
upin humans1
1 study
Pregnancy
upin humans1
Pregnancy increases lipoprotein in humans during pregnancy (nearly doubling between weeks 10 and 35).
“During pregnancy, Lp(a) levels rise substantially, nearly doubling between weeks 10 and 35.”
Reviewduring pregnancybetween weeks 10 and 35
Elevated lipoprotein(a) and adverse pregnancy outcomes
Annals of medicine and surgery (2012)
Traditional cardiovascular risk factors
no changein humans1
1 study
Traditional cardiovascular risk factors
no changein humans1
traditional cardiovascular risk factors were not clearly linked with lipoprotein in humans.
“Lp(a) levels were similar across traditional cardiovascular risk factors categories.”
Humansn = 388
Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology
menopause
upin humans1RR 2.26
1 study
menopause
upin humans1RR 2.26
menopause is linked with higher lipoprotein in humans (women with intermediate visit 1 Lp(a) levels (75-125 nmol/L)) (RR 2.26 (95% CI: 1.31, 3.90)).
“56% of women with intermediate visit 1 Lp(a) levels who transitioned through menopause between visits had incident Lp(a) [≥]125 nmol/L at visit 2, compared with 29% and 28% of women who remained pre- or postmenopausal, representing an age-adjusted risk ratio of 2.26 (95% CI: 1.31, 3.90).”
Humanswomen with intermediate visit 1 Lp(a) levels (75-125 nmol/L)median 4 yearsfemales
Heterogeneity in Lipoprotein(a) Profile Changes Across the Menopausal Transition
medRxivPreprint
Hormonal transition
upin humans1
1 study
Hormonal transition
upin humans1
Hormonal transition increases lipoprotein in humans (hormonal transition).
“Hormonal transition influences the lipid profile by elevating markers such as lipoprotein (a), thereby increasing thrombotic risk.”
Reviewhormonal transitionfemales
Cardiometabolic health in women: differences compared to men
Gaceta medica de Mexico
suPAR
no changein humans1
1 study
suPAR
no changein humans1
suPAR was not clearly linked with lipoprotein in humans (Spearman rho = 0.008; p = 0.60).
“suPAR and Lp(a) were not correlated (Spearman’s rho = 0.008; p = 0.60).”
Humansn = 4,357
AHA Scientific Sessions 2025 abstract
Premenopausal status
no changein humans1
1 study
Premenopausal status
no changein humans1
Premenopausal status showed no clear effect on lipoprotein in humans (Premenopausal versus postmenopausal women in four age-matched studies) (WMD -1.22 mg/dl (95% CI -3.15 to 0.72)).
“Four studies included pre- and postmenopausal women, matched for age, and these found no difference in Lp(a) concentrations between groups”
ReviewPremenopausal versus postmenopausal women in four age-matched studiesfemales
The effect of menopause on lipoprotein (a) concentrations: A systematic review and meta-analysis
Maturitas
PCSK9
upin humans1
1 study
PCSK9
upin humans1
PCSK9 is linked with higher lipoprotein in humans across PCSK9 tertiles; HeFH group only, not controls.
“the Lp(a) concentration and percentage of Lp(a)≥300mg/L were increased by PCSK9 tertiles in HeFH group (both p<0.05)”
Humansacross PCSK9 tertiles; HeFH group only, not controlsPCSK9 tertilesn = 255
Metabolism: clinical and experimental
Associations
222Atherosclerotic cardiovascular disease
upin humans39upin reviews4mixedin humans1HR 1.12–1.44
44 studies
Atherosclerotic cardiovascular disease
upin humans39upin reviews4mixedin humans1HR 1.12–1.44
Lipoprotein is associated with atherosclerotic cardiovascular disease in humans (Primary prevention cohort; high lipoprotein(a)) (Incidence increase per 50 mg/dL higher lipoprotein(a): 2.7 per 1000 person-years (95% CI 2.2-3.2) at ages 70-79; 4.5 (3.7-5.4) at ages 80-100).
“individuals aged 70-100 with high lipoprotein(a) had the highest absolute risk of atherosclerotic cardiovascular disease.”
HumansPrimary prevention cohort; high lipoprotein(a)Median follow-up 12.5 yearsn = 18,322
Lipoprotein(a) and Cardiovascular Disease in Individuals Aged 70-100 Years
AHA Scientific Sessions 2026 abstract
Lipoprotein is linked with a higher risk of atherosclerotic cardiovascular disease in humans (CVD-free participants; one-sample Mendelian randomization) (HR per SD 1.05, 95% CI 1.02–1.08).
“The instrument predicted both outcomes (HR per SD genetically predicted Lp(a) 1.05 [95%CI 1.02-1.08] for ASCVD; 1.12 [1.03-1.23] for AVS)”
HumansCVD-free participants; one-sample Mendelian randomizationper SD genetically predicted Lp(a)n = 28,949
Genetic analysis links a blood fat particle to 60 proteins
AHA Scientific Sessions 2026 abstract
Lipoprotein is associated with atherosclerotic cardiovascular disease in humans (prior ASCVD diagnosis before admission, multivariable analysis) (OR 1.638; 95% CI 1.115–2.405).
“elevated Lp(a) was independently associated with prior ASCVD (OR 1.638; 95% CI 1.115–2.405; p = 0.012)”
Humansprior ASCVD diagnosis before admission, multivariable analysisn = 729
ESC Congress 2026 abstract
Lipoprotein is associated with atherosclerotic cardiovascular disease in humans (RERI 0.60; 95% CI 0.10–1.10).
“Additive interaction was observed for older age (RERI 0.60; 95% CI: 0.10–1.10)”
HumansAdditive interaction between elevated lipoprotein(a) and older age; without ASCVD at baseline>105 versus ≤105 nmol/LUp to 16 yearsn = 19,495
ESC Congress 2026 abstract
Lipoprotein is linked with a higher risk of atherosclerotic cardiovascular disease in humans (primary prevention cohort) (HR 1.12 to 1.18 per 50 mg/dL).
“Hazard ratios per 50 mg/dL higher lipoprotein(a) were similar across all age groups and sexes, ranging from 1.12 to 1.18”
Humansprimary prevention cohort
Lipoprotein(a) and Atherosclerotic Cardiovascular Disease Among Adults Aged 20 to 100 Years
Circulation
Lipoprotein is linked with a higher risk of atherosclerotic cardiovascular disease in humans (HR 1.23 (95% CI 1.19-1.27)).
“highest quintile of TyG, hs-CRP, and Lp(a) was associated with higher ASCVD risk, with hazard ratios (HRs) of 1.32 (95% CI 1.27-1.38), 1.36 (1.30-1.43), and 1.23 (1.19-1.27)”
Humansn = 320,506
Frontiers in endocrinology
Lipoprotein is linked with a higher risk of atherosclerotic cardiovascular disease in humans (OR 1.15, 95% CI 1.07-1.24).
“ln(Lp(a) + 1) was independently associated with the ASCVD (OR 1.15, 95% CI 1.07-1.24)”
Humansn = 23,654
Journal of clinical lipidology
Lipoprotein is linked with a higher risk of atherosclerotic cardiovascular disease in humans (>50 vs ≤50 mg/dL) (AHR 1.36, 95% CI 1.13-1.64).
“When dichotomized (>50 vs ≤50 mg/dL), Lp(a) was associated with ASCVD in adults aged 40 years or older (AHR range, 1.36; 95% CI, 1.13-1.64)”
Humans>50 vs ≤50 mg/dL21.3 years
Traditional and Emerging Lipid Markers for Cardiovascular Risk Assessment in Young vs Older Adults
JAMA network open
Lipoprotein is linked with a higher risk of atherosclerotic cardiovascular disease in humans (HR: 1.24; 95% CI: 1.09-1.41).
“Lp(a) >50 mg/dL (HR: 1.24; 95% CI: 1.09-1.41) and CAC >0 (HR: 2.44; 95% CI: 2.14-2.77) were independently associated with ASCVD risk”
Humansn = 11,319
Journal of the American College of Cardiology
Lipoprotein is linked with a higher risk of atherosclerotic cardiovascular disease in humans (Per 10 nmol/L genetically predicted lipoprotein(a), assessed by Mendelian randomization) (2% higher risk per 10 nmol/L genetically predicted Lp(a)).
“MR showed a 2% higher ASCVD risk per 10 nmol/L genetically predicted Lp(a) (P<2×10−16).”
HumansPer 10 nmol/L genetically predicted lipoprotein(a), assessed by Mendelian randomization
Circulation journal : official journal of the Japanese Circulation Society
All 45Fewer
Coronary artery disease
upin humans20upin reviews3downin humans1OR 1.012–1.31
24 studies
Coronary artery disease
upin humans20upin reviews3downin humans1OR 1.012–1.31
Lipoprotein is associated with coronary artery disease in humans (Per genetically predicted 100 nmol/L increase) (OR 1.31, 95% CI 1.29–1.33).
“genetically predicted lipoprotein(a) was strongly associated with increased risk of coronary artery disease (OR 1.31, 95% CI 1.29–1.33)”
HumansPer genetically predicted 100 nmol/L increasen = 181,522
Journal of thrombosis and thrombolysis
Lipoprotein predicts coronary artery disease in humans (aHR 1.42, 95% CI 1.15-1.74).
“FDRs whose index participant had Lp(a) in the highest decile had higher CAD risk”
HumansIndex participant lipoprotein(a) in the highest decile versus bottom half; incident disease in first-degree relatives13.9 years median follow-up
AHA Scientific Sessions 2026 abstract
Lipoprotein is associated with coronary artery disease in humans (Approximate OR per doubling 1.07, 95% CrI 1.06–1.08).
“Overall, Lp(a) was associated with increased risk of CAD (approximate OR per doubling of Lp(a) 1.07, 95% CrI 1.06 - 1.08).”
HumansPer doubling of genetically inferred Lp(a)n = 657,692
A blood particle’s heart disease link is similar across ancestries
AHA Scientific Sessions 2026 abstract
Lipoprotein is linked with a higher risk of coronary artery disease in humans (Inverse-variance weighted Mendelian randomization) (IVW OR 1.15, 95% CI 1.13–1.17).
“Mendelian randomization confirmed causal effects on PAD (IVW OR=1.05, 95% CI 1.04-1.07) and CAD (IVW OR=1.15, 95% CI 1.13-1.17)”
HumansInverse-variance weighted Mendelian randomization60% femalesn = 378,834
Blood particle linked to differing artery disease risks
AHA Scientific Sessions 2026 abstract
Lipoprotein is associated with coronary artery disease in humans (Hypercholesterolemia; elevated lipoprotein(a) versus non-elevated lipoprotein(a)) (7.4% vs 6.1%; HR 1.20, 95% CI 1.10–1.32).
“new coronary artery disease (7.4% vs 6.1%; RR 1.21, 95% CI 1.10-1.32; HR 1.20, 95% CI 1.10-1.32; P<0.001)”
HumansHypercholesterolemia; elevated lipoprotein(a) versus non-elevated lipoprotein(a)1,095 daysn = 15,925
AHA Scientific Sessions 2026 abstract
Lipoprotein is linked with a higher risk of coronary artery disease in humans (OR 1.21, 95% CI 1.12-1.32).
“CAD (OR 1.21, 95% CI 1.12-1.32)”
Humansn = 23,654
Journal of clinical lipidology
Lipoprotein is associated with coronary artery disease in humans.
“Higher Lp(a) grades were associated with the prevalence of coronary artery disease (CAD)”
Humans
Journal of atherosclerosis and thrombosis
Lipoprotein is associated with coronary artery disease in humans (history of coronary artery disease).
“Elevated Lp(a) was associated with a history of coronary artery disease (p-trend=0.003) and with treatment with high-intensity statins alone (p-trend=0.032) or in combination with ezetimibe (p-trend=0.014).”
Humanshistory of coronary artery diseasen = 388
Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology
Lipoprotein is linked with a higher risk of coronary artery disease in humans (biomarker elevation) (HR 1.20 (95% CI: 1.12-1.29)).
“1.20 (95% CI: 1.12-1.29) for Lp(a)”
Humansbiomarker elevation12 yearsn = 215,695
Journal of the American College of Cardiology
Lipoprotein is linked with a lower risk of coronary artery disease in humans (Lp(a) < 50 mg/dL and IL-6 < median) (HR 0.65, 95% CI 0.56-0.74).
“IL-6 levels below the median and Lp(a) concentrations below 50 mg/dL were also independently and additively associated with lower CHD risk”
HumansLp(a) < 50 mg/dL and IL-6 < mediann = 408,687
European journal of preventive cardiology
All 25Fewer
Cardiovascular disease
upin humans11HR 1.16–2.07
11 studies
Cardiovascular disease
upin humans11HR 1.16–2.07
Lipoprotein is linked with a higher risk of cardiovascular disease in humans (baseline MASLD and elevated Lp(a)) (HR 2.07, 95% CI: 1.39-3.09).
“individuals with baseline MASLD and elevated Lp(a) were independently associated with an increased risk of hard cardiovascular disease (HR 2.07, 95% CI: 1.39-3.09)”
Humansbaseline MASLD and elevated Lp(a)
Metabolism: clinical and experimental
Lipoprotein is linked with a higher risk of cardiovascular disease in humans (elevated Lp(a) >= 125 nmol/L) (10.8% vs 9.0%; HR 1.16, 95% CI 1.06-1.26).
“Elevated Lp(a) was associated with higher risk of any incident CVD event (10.8% vs 9.0%; HR 1.16, 95% CI 1.06-1.26; P <0.001)”
Humanselevated Lp(a) >= 125 nmol/L
ADA Scientific Sessions 2026 abstract
Lipoprotein is linked with a higher risk of cardiovascular disease in humans (primary prevention) (aHR 1.08 (95% CI, 1.06-1.09)).
“Per 1-SD increase, aHRs were 1.08 (95% CI, 1.06-1.09) for log-Lp(a)”
Humansprimary prevention14.6 years median follow-upn = 328,031
Lipoprotein(a), Insulin Resistance, and Cardiovascular Disease in the UK Biobank
Journal of the American Heart Association
Lipoprotein is associated with cardiovascular disease in humans (independent of LDL cholesterol concentrations and other traditional risk factors).
“high lipoprotein(a) remains a genetically determined risk modifier of cardiovascular disease independently of LDL cholesterol concentrations and other traditional risk factors.”
Reviewindependent of LDL cholesterol concentrations and other traditional risk factors
Atherosclerosis
Lipoprotein raises the risk of cardiovascular disease in humans.
“Far from being a benign variant, it acts as a significant amplifier of cardiovascular risk”
Review
The burden of Lipoprotein(a) [Lp(a)] in Africa: A systematic review
PloS one
Lipoprotein raises the risk of cardiovascular disease in humans.
“Lipoprotein(a) has emerged as an important genetically determined cardiovascular risk factor”
Review
Lipid-lowering therapy in transition: implications of the ESC/EAS focused update
Deutsche medizinische Wochenschrift (1946)
Lipoprotein raises the risk of cardiovascular disease in humans.
“lipoprotein(a) (Lp[a]) is an independent, causal, genetic risk factor for cardiovascular disease (CVD) that promotes the progression of high-risk, vulnerable atherosclerotic plaque phenotypes”
Review
Unraveling Emerging Data on Lipoprotein(a)-Driven Cardiovascular Disease via Multiomics: A Review
Global heart
Lipoprotein raises the risk of cardiovascular disease in humans (elevated Lp(a)).
“Observational studies demonstrate markedly increased cardiovascular risk with elevated Lp(a)”
Reviewelevated Lp(a)
The Lipoprotein(a) Implementation Gap: Bridging Evidence and Clinical Practice
Reviews in cardiovascular medicine
Lipoprotein raises the risk of cardiovascular disease in familial hypercholesterolemia.
“mounting clinical evidence indicates that lowering LDL-C pharmacologically will not offset the specific cardiovascular risk stemming from elevated Lp(a) in FH.”
Reviewin familial hypercholesterolemia
Lipoprotein(a) in familial hypercholesterolemia
Current opinion in lipidology
Lipoprotein raises the risk of cardiovascular disease in humans.
“Lipoprotein(a) [Lp(a)] is a well recognised contributor in the development of cardiovascular disease.”
Review
Lipoprotein(a): the neglected risk factor in cardiovascular health
Frontiers in cardiovascular medicine
All 11Fewer
Major adverse cardiovascular events
upin humans10no changein humans1HR 1.06–2.6
10 studies
Major adverse cardiovascular events
upin humans10no changein humans1HR 1.06–2.6
Lipoprotein is associated with major adverse cardiovascular events in humans (LDL-C <70 mg/dL on statin and/or ezetimibe therapy) (HR 1.08; 95% CI 1.04–1.12).
“patients with elevated Lp(a) had higher rates of MACE (HR 1.08; 95% CI 1.04-1.12; P<.001)”
HumansLDL-C <70 mg/dL on statin and/or ezetimibe therapyLp(a) ≥50 mg/dL or ≥125 nmol/LMedian follow-up of 2.6 to 3.1 years42.3% femalesn = 41,750
AHA Scientific Sessions 2026 abstract
Lipoprotein is associated with major adverse cardiovascular events in humans (Stable CAD; LDL-C ≥70 mg/dL; Lp(a) ≥50 versus <50 mg/dL) (Adjusted sHR 1.29, 95% CI 1.09–1.52; p=0.004).
“elevated Lp(a) was independently associated with MACE in those with LDL-C ≥70 mg/dL”
HumansStable CAD; LDL-C ≥70 mg/dL; Lp(a) ≥50 versus <50 mg/dL5 yearsn = 3,546
AHA Scientific Sessions 2026 abstract
Lipoprotein is associated with major adverse cardiovascular events in humans.
“When adjusted for both diabetes and smoking Lp(a) also remained a significant predictor of MACE”
HumansRecent acute coronary syndrome; placebo group on optimized statin therapy; adjusted for smoking and diabetesMedian follow-up 2.8 yearsn = 9,462
ESC Congress 2026 abstract
Lipoprotein is associated with major adverse cardiovascular events in humans (Patients undergoing percutaneous coronary intervention) (Adjusted HR per 1 SD 1.07, 95% CI 1.02–1.12).
“Over five years, higher Lp(a) was independently associated with an increased risk of MACE”
HumansPatients undergoing percutaneous coronary intervention5 yearsn = 5,942
ESC Congress 2026 abstract
Lipoprotein is associated with major adverse cardiovascular events in humans (Secondary prevention subgroup; no significant predictive association).
“in men Lp(a) predicted MACE only in primary prevention subgroups (per-SD HR 1.11-1.15; p < 0.001) but not in secondary prevention (p = 0.65).”
HumansSecondary prevention subgroup; no significant predictive associationMedian follow-up 15.2 yearsmales
Atherosclerosis
Lipoprotein predicts major adverse cardiovascular events in humans Across baseline cardiovascular risk subgroups (Per-SD HR 1.06–1.11 across subgroups).
“Lp(a) predicted MACE independently but heterogeneously: in women associations were consistent across subgroups (per-SD HR 1.06-1.11; p ≤ 0.005)”
HumansAcross baseline cardiovascular risk subgroupsMedian follow-up 15.2 yearsfemales
Atherosclerosis
Lipoprotein is associated with major adverse cardiovascular events in humans (Patients undergoing percutaneous coronary intervention) (Adjusted HR per 1 SD 1.06, 95% CI 1.01–1.12).
“higher Lp(a) was independently associated with risk of MACE (adjusted hazard ratio [HR] per 1 SD 1.06 [95% CI 1.01-1.12]; P = .015)”
HumansPatients undergoing percutaneous coronary intervention5 yearsn = 5,942
Journal of clinical lipidology
Lipoprotein is linked with a higher risk of major adverse cardiovascular events in humans across high-risk groups in general population.
“MACE rates varied by group and increased progressively with higher Lp(a) thresholds.”
Humansacross high-risk groups in general population
European journal of preventive cardiology
Lipoprotein is linked with a higher risk of major adverse cardiovascular events in humans (overall cohort).
“elevated Lp(a) was associated with MACE in the overall cohort”
Humansoverall cohortmedian 15.7 yearsn = 337,164
Research SquarePreprint
Lipoprotein predicts major adverse cardiovascular events in humans (Symptomatic, advanced coronary artery calcification; lipoprotein(a) ≥50 versus <50 mg/dL) (37.7% vs. 15.8%; adjusted HR 2.60, 95% CI 1.55–4.35).
“the elevated Lp(a) cohort had a significantly higher MACE rate (37.7% vs. 15.8%; adjusted hazard ratio [aHR] 2.60, 95% CI 1.55-4.35, p < 0.001).”
HumansSymptomatic, advanced coronary artery calcification; lipoprotein(a) ≥50 versus <50 mg/dLMedian follow-up of 17.2 monthsn = 292
International journal of cardiology. Cardiovascular risk and prevention
All 11Fewer
Calcific aortic valve stenosis
upin humans7upin reviews2
9 studies
Calcific aortic valve stenosis
upin humans7upin reviews2
Lipoprotein raises the risk of calcific aortic valve stenosis in humans.
“and it is also causally implicated in calcific aortic valve stenosis.”
Review
Lipoprotein(a) in the statin era: from risk marker to therapeutic target
Frontiers in pharmacology
Lipoprotein raises the risk of calcific aortic valve stenosis in humans (elevated concentrations (particularly ≥ 125 nmol/L)).
“individuals with elevated concentrations (particularly ≥ 125 nmol/L) face substantial incremental ASCVD and CAVS risk.”
Reviewelevated concentrations (particularly ≥ 125 nmol/L)
Lipoprotein(a) in Japan: An Expert Consensus Statement
Journal of atherosclerosis and thrombosis
Lipoprotein raises the risk of calcific aortic valve stenosis.
“causal, independent risk factor for atherosclerotic cardiovascular disease and calcific aortic valve stenosis”
Review
Lipoprotein(a) measurement: challenges and opportunities
Clinical chemistry and laboratory medicine
Lipoprotein raises the risk of calcific aortic valve stenosis in humans (genetically determined).
“independent and causal risk factor for atherosclerotic cardiovascular disease (ASCVD) and calcific aortic valve stenosis (CAVS)”
Reviewgenetically determined
Journal of clinical medicine
Lipoprotein raises the risk of calcific aortic valve stenosis in humans (elevated Lp(a)).
“Lipoprotein(a) [Lp(a)] is a causal, genetically determined risk factor for atherosclerotic cardiovascular disease (ASCVD) and calcific aortic valve stenosis (CAVS).”
Reviewelevated Lp(a)
Lipoprotein(a) and Cardiovascular Disease: From Genetic Risk Factor to Therapeutic Target
Cells
Lipoprotein raises the risk of calcific aortic valve stenosis in humans (genetically determined).
“independent risk factor for atherosclerotic cardiovascular disease, including acute coronary syndrome, peripheral arterial disease, and stroke, as well as calcific aortic stenosis”
Reviewgenetically determined
The Canadian journal of cardiology
Lipoprotein raises the risk of calcific aortic valve stenosis in humans (genetically determined).
“Lipoprotein(a) [Lp(a)] is a genetically determined risk factor for atherosclerotic cardiovascular disease (ASCVD) and calcific aortic valve stenosis (CAVS)”
Reviewgenetically determined
Korean circulation journal
Lipoprotein is associated with calcific aortic valve stenosis.
“Lp(a) is strongly associated with calcific aortic valve stenosis (CAVS), coronary artery disease (CAD), peripheral arterial disease (PAD)”
Review
Lipoprotein(a) and cardiovascular and valvular diseases: A genetic epidemiological perspective
Atherosclerosis
Lipoprotein predicts calcific aortic valve stenosis in humans.
“Elevated plasma lipoprotein(a) and oxidized phospholipids predict progression of pre-existing aortic stenosis and need for aortic valve replacement.”
Review
Lipoprotein(a) and oxidized phospholipids in calcific aortic valve stenosis
Current opinion in cardiology
Mortality
upin humans8HR 1.13–1.58
8 studies
Mortality
upin humans8HR 1.13–1.58
Lipoprotein is associated with mortality in humans (Baseline coronary artery disease).
“Restricted cubic spline analysis demonstrated a positive dose-response relationship between Lp(a) levels and the risks of cardiovascular and all-cause mortality.”
HumansBaseline coronary artery diseaseMedian follow-up of 5.2 years23.5% femalesn = 51,489
ESC Congress 2026 abstract
Lipoprotein is linked with a higher risk of mortality in humans (CKM stage 3) (HR 1.13, 95% CI 1.01–1.25).
“high Lp(a) was associated with a modestly higher risk in CKM stage 3 (HR, 1.13; 95% CI, 1.01–1.25; P = 0.03)”
HumansCKM stage 3median 15.7 yearsn = 337,164
Research SquarePreprint
Lipoprotein is linked with a higher risk of mortality in humans (acute decompensated heart failure) (adjusted HR 1.21 (95% CI 1.05-1.39)).
“In all patients, log-transformed Lp(a) was significantly associated with mortality (adjusted HR 1.21; 95% CI, 1.05-1.39; P = 0.007)”
Humansacute decompensated heart failure4.1 years (median)n = 2,610
International journal of cardiology. Cardiovascular risk and prevention
Lipoprotein is associated with mortality in high baseline CV risk group (HR 1.25, 95% CI 1.02-1.53).
“In the high-risk group, Lp(a) >75 mg/dL was associated with higher all-cause (HR: 1.25; 95% CI: 1.02-1.53)”
Humansin high baseline CV risk group>75 mg/dL
European journal of preventive cardiology
Lipoprotein is linked with a higher risk of mortality in humans (primary prevention, >95th percentile (>100 mg/dL) vs <50th percentile) (adjusted HR: 1.37; 95%CI: 1.07–1.75).
“only those with Lp(a) >95th percentile (>100 mg/dL) showed a significantly higher risk of ACM (adjusted HR: 1.37; 95%CI: 1.07–1.75; p=0.012”
Humansprimary prevention, >95th percentile (>100 mg/dL) vs <50th percentileup to 15 years54% malessn = 42,770
AHA Scientific Sessions 2025 abstract
Lipoprotein is associated with mortality in humans (EPIC-Norfolk participants) (HR 1.17, 95% CI 1.08–1.27).
“those with Lp(a) levels ≥50 mg/dL had an increased hazard ratio (HR) for all-cause (HR=1.17, 95% CI=1.08-1.27)”
HumansEPIC-Norfolk participantsLp(a) ≥50 mg/dL versus <50 mg/dL20 yearsn = 18,720
Long-Term Exposure to Elevated Lipoprotein(a) Levels, Parental Lifespan and Risk of Mortality
bioRxiv (Cold Spring Harbor Laboratory)Preprint
Lipoprotein is associated with mortality in humans After bioprosthetic aortic valve replacement; elevated versus lower serum lipoprotein(a) (HR 1.53, 95% CI 1.13–2.08).
“Elevated Lp(a) was associated with significantly increased risks of SVD and all-cause mortality following bioprosthetic aortic valve replacement.”
ReviewAfter bioprosthetic aortic valve replacement; elevated versus lower serum lipoprotein(a)
Elevated Lipoprotein(a) and Bioprosthetic Valve Outcomes: A Sytematic Review and Meta-Analysis
AHA Scientific Sessions 2026 abstract
Lipoprotein is associated with mortality in humans (maintenance dialysis patients; exploratory meta-analysis) (HR 1.58, 95% CI 1.24–2.02).
“Exploratory meta-analyses revealed associations between elevated Lp(a) levels and all-cause mortality (HR: 1.58; 95% CI: 1.24-2.02)”
Reviewmaintenance dialysis patients; exploratory meta-analysis
Lipids in health and disease
Myocardial infarction
upin humans7upin reviews1HR 1.09–2.61
8 studies
Myocardial infarction
upin humans7upin reviews1HR 1.09–2.61
Lipoprotein is associated with myocardial infarction in humans (Elevated lipoprotein(a) >50 mg/dL; adjusted for traditional cardiovascular risk factors) (HR 1.44, 95% CI 1.42–1.46).
“followed by MI (HR 1.44, 95% CI 1.42-1.46), PAD (HR 1.31, 95% CI 1.28-1.33), and stroke (HR 1.15, 95% CI 1.13-1.16).”
HumansElevated lipoprotein(a) >50 mg/dL; adjusted for traditional cardiovascular risk factors
AHA Scientific Sessions 2026 abstract
Lipoprotein is linked with a higher risk of myocardial infarction in humans (OR 1.78, 95% CI 1.31-2.41).
“previous MI (OR 1.78, 95% CI 1.31-2.41)”
Humansn = 23,654
Journal of clinical lipidology
Lipoprotein is linked with a higher risk of myocardial infarction in humans (elevated Lp(a) >= 125 nmol/L) (2.6% vs 2.0%; HR 1.20, 95% CI 1.00-1.43).
“and myocardial infarction (2.6% vs 2.0%; HR 1.20, 95% CI 1.00-1.43; P = 0.047)”
Humanselevated Lp(a) >= 125 nmol/L
ADA Scientific Sessions 2026 abstract
Lipoprotein is linked with a higher risk of myocardial infarction in humans (very high Lp(a) (>230 nmol/L) vs low Lp(a) (≤7 nmol/L)) (P = 0.012).
“Individuals with very high Lp(a) had significantly lower event-free survival time for the diagnosis of obstructive CAD and occurrence of MI (P = 0.006 and P = 0.012, respectively).”
Humansvery high Lp(a) (>230 nmol/L) vs low Lp(a) (≤7 nmol/L)
JACC. Advances
Lipoprotein is linked with a higher risk of myocardial infarction in humans (top vs bottom quintile, adjusted for CV risk factors and other two biomarkers) (HR 1.09 (95% CI: 1.08–1.11)).
“Adjusted HRs for MI comparing the top versus bottom quintiles were 1.09 (95% CI: 1.08–1.11) for Lp(a)”
Humanstop vs bottom quintile, adjusted for CV risk factors and other two biomarkers15-year median follow-upn = 306,183
AHA Scientific Sessions 2025 abstract
Lipoprotein is linked with a higher risk of myocardial infarction in humans (no baseline atherosclerotic cardiovascular disease) (adjusted HR, 2.61 (95% CI, 1.48-4.61)).
“strongest association was present between lipoprotein(a) and fatal or nonfatal myocardial infarction (women: adjusted HR, 2.61 [95% CI, 1.48-4.61]”
Humansno baseline atherosclerotic cardiovascular diseasefemales
Journal of the American Heart Association
Lipoprotein is associated with myocardial infarction.
“it carries a well-established association with myocardial infarction, stroke, and aortic stenosis”
Review
Residual cardiovascular risk beyond LDL-cholesterol control: what remains unaddressed?
American journal of cardiovascular disease
Myocardial infarction is associated with lipoprotein in humans.
“younger are more likely to be men, have familial-combined hyperlipidaemia and increased levels of lipoprotein-a.”
Review
Risk factors profile of young and older patients with myocardial infarction
Cardiovascular research
Aortic valve stenosis
upin humans7HR 1.39–1.6
7 studies
Aortic valve stenosis
upin humans7HR 1.39–1.6
Lipoprotein is linked with a higher risk of aortic valve stenosis in humans (CVD-free participants; one-sample Mendelian randomization) (HR per SD 1.12, 95% CI 1.03–1.23).
“The instrument predicted both outcomes (HR per SD genetically predicted Lp(a) 1.05 [95%CI 1.02-1.08] for ASCVD; 1.12 [1.03-1.23] for AVS)”
HumansCVD-free participants; one-sample Mendelian randomizationper SD genetically predicted Lp(a)n = 28,949
Genetic analysis links a blood fat particle to 60 proteins
AHA Scientific Sessions 2026 abstract
Lipoprotein is associated with aortic valve stenosis in humans (Elevated lipoprotein(a) >50 mg/dL; adjusted for traditional cardiovascular risk factors) (HR 1.60, 95% CI 1.55–1.64).
“Elevated Lp(a) had the strongest association with AS risk (HR 1.60, 95% CI 1.55-1.64)”
HumansElevated lipoprotein(a) >50 mg/dL; adjusted for traditional cardiovascular risk factors
AHA Scientific Sessions 2026 abstract
Lipoprotein is associated with aortic valve stenosis in humans (HR 1.39 with LDL-C <55 mg/dL; HR 1.35 with LDL-C <70 mg/dL).
“In both LDL-C strata, higher Lp(a) was associated with significantly greater residual risk of recurrent MI, ischemic stroke, peripheral artery disease, and aortic stenosis.”
HumansPrior myocardial infarction and LDL-C <55 mg/dL; higher versus lower lipoprotein(a), using a threshold of 125 nmol/L or 50 mg/dL; 3,827 patients per groupn = 3,827
AHA Scientific Sessions 2026 abstract
Lipoprotein raises the risk of aortic valve stenosis in humans.
“independent risk factor for atherosclerotic cardiovascular disease (ASCVD) and aortic valve stenosis.”
Review
Lipoprotein(a): Actionable today, treatable tomorrow?
Australian journal of general practice
Lipoprotein raises the risk of aortic valve stenosis in humans.
“Epidemiological and Mendelian randomisation studies consistently demonstrate a strong and likely causal association between elevated lipoprotein(a) and AS.”
Review
Lipoprotein(a) and Aortic Stenosis: From Genetic Risk to Emerging Therapeutic Strategies
European cardiology
Lipoprotein raises the risk of aortic valve stenosis in humans (elevated levels).
“Lipoprotein(a) [Lp(a)] is a risk factor for atherosclerotic cardiovascular disease and aortic valve stenosis.”
Reviewelevated levels
Lipoprotein(a) - the hereditary risk factor for cardiovascular disease
Lakartidningen
Lipoprotein raises the risk of aortic valve stenosis in humans.
“Lipoprotein(a) [Lp(a)] constitutes an independent, causal risk factor for ASCVD and aortic valve stenosis.”
Review
Archives of medical science : AMS
Calcific aortic valve disease
upin humans5
5 studies
Calcific aortic valve disease
upin humans5
Lipoprotein is linked with a higher risk of calcific aortic valve disease in humans (> 30 mg/dL vs ≤ 30 mg/dL) (2–4 fold).
“The prevalence of CAVD in non-elderly populations was markedly 2–4 fold greater in the higher Lp(a) group (> 30 mg/dL) than in the lower Lp(a) group (≤ 30 mg/dL).”
Humans> 30 mg/dL vs ≤ 30 mg/dL> 30 mg/dL
Decoding calcific aortic valve disease: superior predictive power of time-weighted lipoprotein(a)
Lipids in health and disease
Calcific aortic valve disease is associated with lipoprotein in humans (> 2-fold).
“The average Lp(a) level in the young populations with CAVD was more than twice that in the No-CAVD group, particularly among those aged 55 years or younger.”
Humans
Decoding calcific aortic valve disease: superior predictive power of time-weighted lipoprotein(a)
Lipids in health and disease
Lipoprotein raises the risk of calcific aortic valve disease in humans (elevated Lp(a)).
“Genetic, epidemiological, and mechanistic evidence supports a causal role for elevated Lp(a) in atherosclerotic cardiovascular disease and calcific aortic valve disease.”
Reviewelevated Lp(a)
Lipoprotein(a) Inhibition: Current Evidence, Therapeutic Landscape, and Future Directions
Reviews in cardiovascular medicine
Lipoprotein raises the risk of calcific aortic valve disease in humans (elevated plasma levels).
“Elevated plasma lipoprotein(a) [Lp(a)] levels represent a predominantly genetically determined risk factor for atherosclerotic cardiovascular disease and calcific aortic valve disease (CAVD).”
Reviewelevated plasma levels
Role of Lipoprotein(a) in Aortic Valve Calcification: Inflammatory and Oxidative Mechanisms Involved
International journal of molecular sciences
Lipoprotein raises the risk of calcific aortic valve disease in humans.
“has been established as an independent and causal risk factor for atherosclerotic cardiovascular disease (ASCVD) and calcific aortic valve disease (CAVD)”
Review
Journal of the Formosan Medical Association = Taiwan yi zhi
Lipoprotein raises the risk of calcific aortic valve disease in humans.
“Elevated levels of lipoprotein(a) [Lp(a)] have been identified as an independent and causal risk factor for atherosclerotic cardiovascular disease (ASCVD) and, more recently, calcific aortic valve disease (CAVD).”
Review
Lipoprotein(a): Expanding our knowledge of aortic valve narrowing
Trends in cardiovascular medicine
Ischemic stroke
upin humans4upin reviews1OR 1.01–1.44
5 studies
Ischemic stroke
upin humans4upin reviews1OR 1.01–1.44
Lipoprotein is associated with ischemic stroke in humans (OR 1.44, 95% CI 1.25-1.66).
“Among Black individuals, elevated Lp(a) was associated with increased odds of stroke (OR 1.44, 95% CI 1.25-1.66)”
HumansBlack individuals; high (≥100 mg/dL or ≥250 nmol/L) versus low (<30 mg/dL or <75 nmol/L) lipoprotein(a)
Cardiovascular Risk Associated with High vs Low Lipoprotein(a) Across Black and White Individuals
AHA Scientific Sessions 2026 abstract
Lipoprotein is associated with ischemic stroke in humans (HR 1.34 with LDL-C <55 mg/dL; HR 1.33 with LDL-C <70 mg/dL).
“In both LDL-C strata, higher Lp(a) was associated with significantly greater residual risk of recurrent MI, ischemic stroke, peripheral artery disease, and aortic stenosis.”
HumansPrior myocardial infarction and LDL-C <55 mg/dL; higher versus lower lipoprotein(a), using a threshold of 125 nmol/L or 50 mg/dL; 3,827 patients per groupn = 3,827
AHA Scientific Sessions 2026 abstract
Lipoprotein predicts ischemic stroke in humans (Symptomatic, advanced coronary artery calcification; lipoprotein(a) ≥50 versus <50 mg/dL) (Adjusted HR 7.14).
“Elevated Lp(a) independently predicted increased risks of ischemic stroke (aHR 7.14) and in-stent restenosis (aHR 2.78).”
HumansSymptomatic, advanced coronary artery calcification; lipoprotein(a) ≥50 versus <50 mg/dLMedian follow-up of 17.2 monthsn = 292
International journal of cardiology. Cardiovascular risk and prevention
Lipoprotein is linked with a higher risk of ischemic stroke in humans (per 100 nmol/L increase in genetically predicted Lp(a) levels) (OR 1.04 (95% CI, 1.02-1.07), P=2.05×10−4).
“Genetically predicted Lp(a) levels associated with significantly increased risk of all-cause ischemic stroke (odds ratio [OR], 1.04 [95% CI, 1.02-1.07], P=2.05×10−4)”
Humansper 100 nmol/L increase in genetically predicted Lp(a) levels
Genetically Predicted Levels of Lipoprotein(a) and Risk of Cerebrovascular Disease
Journal of the American Heart Association
Lipoprotein is associated with ischemic stroke (OR 1.01, 95% CI 0.99-1.02; not statistically significant).
“the association between Lp(a) and IS was not statistically significant (OR 1.01, 95% CI 0.99-1.02; p = 0.26, I 2 = 57%)”
Review
Frontiers in neurology
Race and ethnicity
mixedin humans1
1 study
Race and ethnicity
mixedin humans1
race and ethnicity is associated with lipoprotein in humans (baseline values before treatment) (median baseline 108.6 nmol/L in Black or African American participants vs 36.1 nmol/L in White participants).
“baseline Lp(a) levels varied by race”
Human trialbaseline values before treatmentn = 3,187
An oral drug lowers lipoprotein(a) across patient groups
ESC Congress 2026 abstract
Oxidized phospholipids on apolipoprotein
downin humans1
1 study
Oxidized phospholipids on apolipoprotein
downin humans1
Oxidized phospholipids on apolipoprotein is associated with lipoprotein in humans (percent change in Lp(a) during lepodisiran treatment).
“Percent change in OxPL-apo(a) correlated more closely than OxPL-apoB with percent change in Lp(a) than did OxPL-apoB.”
Human trialpercent change in Lp(a) during lepodisiran treatment
Journal of the American College of Cardiology
All 222Fewer
Funding
41 grants since 2016National Heart, Lung, and Blood Institute$12MNational Eye Institute$5.2MNational Institute on Aging$5.5M
Decoding the immunogenetic architecture of lipoprotein(a)-driven cardiovascular inflammation
National Heart, Lung, and Blood InstituteUniversity of Colorado, Denver$42.2K2026–2029
Aspirin for Primary Prevention of Cardiovascular Disease in Patients with Elevated Lipoprotein(a)
National Heart, Lung, and Blood InstituteUniversity of California, San Diego$169K2023–2028
National Heart, Lung, and Blood InstituteJohns Hopkins University$655K2024–2029
Gene therapy targeting CFH and lipoprotein dynamics in AMD
National Eye InstituteDuke University$683K2025–2028
National Institute on AgingUniversity of Minnesota$725K2023–2027
Lipoprotein Metabolism and Excess Cardiometabolic Risk in South Asians
National Heart, Lung, and Blood InstituteUT Southwestern Medical Center$399K2022–2027
2026 Kern Lipid Conference; Lipids and lipoproteins in Neurodegenerative and Cardiometabolic disease
National Institute on AgingUniversity of Colorado, Denver$41.7K2026–2027
Phenotypic consequences of lipoprotein(a)
National Heart, Lung, and Blood InstituteUniv of North Carolina Chapel Hill$1.3M2025–2028
American Heart AssociationJohns Hopkins University$9.9K2026–2027
Next-Generation Cardiovascular Risk Assessments Via State-Of-The-Art Lipoprotein Characterization
National Heart, Lung, and Blood InstituteElectronic Biosciences$400K2024–2026